The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical ...

A new study found users of one drug lost almost 50 percent more weight that users of Wegovy. People taking Eli Lilly’s ...

Reducing exposure to medicines is always a good thing if similar clinical outcomes can be achieved, and the study suggests it ...

In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...

The popular weight loss medications produced different results in patients who participated in a trial, and here’s what ...

Within six months, the drug reduced the risk of cardiovascular death by 50% and cut the risk of needing urgent treatment due ...

The National Institute for Health and Care Excellence (Nice) previously stopped its appraisal of semaglutide (Wegovy) for use ...

Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...

The Trump administration on Monday singled out powerful new weight-loss drugs including Wegovy and Zepbound as targets in its ...

Qatar and Denmark can broaden their healthcare partnership beyond pharmaceuticals, creating new opportunities in public ...